Not available
Quote | Fluidigm Corporation (NASDAQ:FLDM)
Last: | $3.71 |
---|---|
Change Percent: | -7.02% |
Open: | $4.05 |
Close: | $3.71 |
High: | $4.05 |
Low: | $3.66 |
Volume: | 526,846 |
Last Trade Date Time: | 04/05/2022 04:54:08 pm |
News | Fluidigm Corporation (NASDAQ:FLDM)
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the introduction of new solutions that add automation and flexibilit...
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with glob...
Message Board Posts | Fluidigm Corporation (NASDAQ:FLDM)
Subject | By | Source | When |
---|---|---|---|
$FLDM bot this 30 min chart today.. | manysevens | investorshub | 11/25/2021 2:35:03 AM |
No. I think they are in deep doo | Eggplant | investorshub | 11/08/2021 10:36:44 PM |
$FLDM Back from the dead? | LongTimeObserver | investorshub | 11/06/2020 7:08:34 PM |
Pffft! $FLDM | LongTimeObserver | investorshub | 10/29/2020 4:02:59 PM |
06:28 $FLDM Fluidigm: Trump Administration provides saliva test at surge | Atlanta1 | investorshub | 10/19/2020 12:27:10 PM |
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the introduction of new solutions that add automation and flexibilit...
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with glob...
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Pr...